LIGAND PHARMACEUTICAL INC (LGNXZ)
USD 0.0
(18.18%)
USD 0.0
(18.18%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 23.96 Million USD | 80.3% |
| 2022 | 13.29 Million USD | -51.35% |
| 2021 | 27.32 Million USD | 3.17% |
| 2020 | 26.48 Million USD | 263.03% |
| 2019 | 7.29 Million USD | 2.41% |
| 2018 | 7.12 Million USD | 62.91% |
| 2017 | 4.37 Million USD | 127.41% |
| 2016 | 1.92 Million USD | 17.76% |
| 2015 | 1.63 Million USD | 507.06% |
| 2014 | 269 Thousand USD | -80.68% |
| 2013 | 1.39 Million USD | -17.97% |
| 2012 | 1.69 Million USD | 30.44% |
| 2011 | 1.3 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 3.85 Million USD | -58.68% |
| 2005 | 9.33 Million USD | -20.72% |
| 2004 | 11.77 Million USD | 0.0% |
| 2003 | - USD | 100.0% |
| 2002 | -1.08 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 20.7 Million USD | -2.95% |
| 2024 Q1 | 21.33 Million USD | -10.98% |
| 2023 Q2 | 26.9 Million USD | 92.03% |
| 2023 Q1 | 14.01 Million USD | 5.39% |
| 2023 Q3 | 25.39 Million USD | -5.63% |
| 2023 Q4 | 23.96 Million USD | -5.6% |
| 2023 FY | 23.96 Million USD | 80.3% |
| 2022 Q1 | 25.61 Million USD | -6.27% |
| 2022 FY | 13.29 Million USD | -51.35% |
| 2022 Q2 | 24.77 Million USD | -3.28% |
| 2022 Q4 | 13.29 Million USD | -40.46% |
| 2022 Q3 | 22.32 Million USD | -9.88% |
| 2021 Q2 | 39.94 Million USD | 8.16% |
| 2021 Q1 | 36.93 Million USD | 39.43% |
| 2021 FY | 27.32 Million USD | 3.17% |
| 2021 Q4 | 27.32 Million USD | -17.18% |
| 2021 Q3 | 32.99 Million USD | -17.4% |
| 2020 Q4 | 26.48 Million USD | 97.22% |
| 2020 Q1 | 7.32 Million USD | 0.33% |
| 2020 Q2 | 3.7 Million USD | -49.43% |
| 2020 Q3 | 13.43 Million USD | 262.78% |
| 2020 FY | 26.48 Million USD | 263.03% |
| 2019 Q1 | 11.9 Million USD | 67.11% |
| 2019 Q4 | 7.29 Million USD | 11.13% |
| 2019 Q3 | 6.56 Million USD | -31.88% |
| 2019 FY | 7.29 Million USD | 2.41% |
| 2019 Q2 | 9.63 Million USD | -19.04% |
| 2018 Q4 | 7.12 Million USD | -12.44% |
| 2018 Q2 | 9.52 Million USD | -9.6% |
| 2018 Q1 | 10.53 Million USD | 140.82% |
| 2018 Q3 | 8.13 Million USD | -14.54% |
| 2018 FY | 7.12 Million USD | 62.91% |
| 2017 Q2 | 6.8 Million USD | -10.75% |
| 2017 FY | 4.37 Million USD | 127.41% |
| 2017 Q4 | 4.37 Million USD | -12.66% |
| 2017 Q3 | 5 Million USD | -26.46% |
| 2017 Q1 | 7.62 Million USD | 296.72% |
| 2016 Q3 | 4.02 Million USD | 5.01% |
| 2016 FY | 1.92 Million USD | 17.76% |
| 2016 Q4 | 1.92 Million USD | -52.25% |
| 2016 Q2 | 3.83 Million USD | 119.14% |
| 2016 Q1 | 1.75 Million USD | 7.16% |
| 2015 Q2 | 802 Thousand USD | -71.57% |
| 2015 Q1 | 2.82 Million USD | 948.7% |
| 2015 FY | 1.63 Million USD | 507.06% |
| 2015 Q4 | 1.63 Million USD | 33.74% |
| 2015 Q3 | 1.22 Million USD | 52.24% |
| 2014 Q3 | 1.07 Million USD | 31.09% |
| 2014 Q2 | 817 Thousand USD | -58.08% |
| 2014 Q1 | 1.94 Million USD | 40.01% |
| 2014 FY | 269 Thousand USD | -80.68% |
| 2014 Q4 | 269 Thousand USD | -74.88% |
| 2013 FY | 1.39 Million USD | -17.97% |
| 2013 Q2 | 2.26 Million USD | -20.19% |
| 2013 Q3 | 1.83 Million USD | -18.85% |
| 2013 Q1 | 2.83 Million USD | 67.24% |
| 2013 Q4 | 1.39 Million USD | -24.27% |
| 2012 Q1 | 1.34 Million USD | 3.38% |
| 2012 FY | 1.69 Million USD | 30.44% |
| 2012 Q2 | 2.69 Million USD | 100.59% |
| 2012 Q3 | 2.54 Million USD | -5.56% |
| 2012 Q4 | 1.69 Million USD | -33.4% |
| 2011 Q3 | 1.96 Million USD | -24.44% |
| 2011 Q1 | 4.21 Million USD | 0.0% |
| 2011 Q2 | 2.59 Million USD | -38.41% |
| 2011 Q4 | 1.3 Million USD | -33.62% |
| 2011 FY | 1.3 Million USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 FY | - USD | -100.0% |
| 2006 Q2 | 8.46 Million USD | 2.85% |
| 2006 Q4 | 3.85 Million USD | -23.48% |
| 2006 FY | 3.85 Million USD | -58.68% |
| 2006 Q3 | 5.03 Million USD | -40.49% |
| 2006 Q1 | 8.23 Million USD | -11.8% |
| 2005 Q3 | 6.86 Million USD | 8.53% |
| 2005 Q4 | 9.33 Million USD | 35.89% |
| 2005 FY | 9.33 Million USD | -20.72% |
| 2005 Q1 | 6.89 Million USD | -41.42% |
| 2005 Q2 | 6.32 Million USD | -8.24% |
| 2004 Q2 | 11.75 Million USD | 20.29% |
| 2004 Q1 | 9.77 Million USD | 18.25% |
| 2004 Q4 | 11.77 Million USD | 0.0% |
| 2004 FY | 11.77 Million USD | 0.0% |
| 2003 Q4 | 8.26 Million USD | 37.59% |
| 2003 Q1 | 5.39 Million USD | 597.24% |
| 2003 Q2 | 4.8 Million USD | -10.92% |
| 2003 FY | - USD | 100.0% |
| 2003 Q3 | 6 Million USD | 24.95% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | -1.08 Million USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | 3.15 Million USD | 0.0% |
| 2002 Q4 | -1.08 Million USD | -134.39% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | - USD | -Infinity% |
| Allstar Health Brands, Inc. | - USD | -Infinity% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 129.52 Million USD | 81.494% |
| Café Serendipity Holdings, Inc. | - USD | -Infinity% |
| Decision Diagnostics Corp. | - USD | -Infinity% |
| Health Advance Inc. | 0.64 USD | -3745156150.0% |
| HealthWarehouse.com, Inc. | 509.11 Thousand USD | -4607.964% |
| MedGen, Inc. | - USD | -Infinity% |
| Omni Health, Inc. | 380.1 Thousand USD | -6205.823% |
| Oxford Investments Holdings Inc. | 124.35 Thousand USD | -19175.122% |
| Pineapple, Inc. | 4710.00 USD | -508795.966% |
| ScripsAmerica, Inc. | 735.76 Thousand USD | -3157.707% |